Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387821![]() (N-(2-Cyanoethyl)-2-(1-((1r,4r)-4-(cyanomethyl)cycl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493089![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493066![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493067![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | KEGG PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493068![]() (2-((1r,4r)-4-(2-(1H-1,2,4-Triazol-3-yl)imidazo[4,5...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387823![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493070![]() (2-((1r,4r)-4-(2-(Oxazol-4-yl)imidazo[4,5-d]pyrrolo...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493071![]() (2-((1r,4r)-4-(2-(2-(4-Hydroxypiperidin-1-yl)-2-oxo...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493072![]() (2-Cyano-N-((1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493073![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493074![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493075![]() (2-((1r,4r)-4-(2-(2H-1,2,3-Triazol-4-yl)imidazo[4,5...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493076![]() ((E)-N-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493078![]() (2-((1r,4r)-4-(2-(2-(3-Hydroxyazetidin-1-yl)-2-oxoe...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493079![]() (N-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-2-(1-((1r,4r...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493080![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493081![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387824![]() (N-(2-Cyano-2-methylpropyl)-2-(1-((1r,4r)-4-(cyanom...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493083![]() (N-(4-Cyanobicyclo[2.2.1]heptan-1-yl)-2-(1-((1r,4r)...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493084![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493085![]() (2-((1r,4r)-4-(2-((1H-Pyrazol-5-yl)methyl)imidazo[4...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM50527405![]() (CHEMBL4456630 | US10981911, Example 26) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493087![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493088![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493065![]() (2-((1r,4r)-4-(2-(2-Oxo-2-(4-(trifluoromethyl)piper...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.100 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493096![]() (N-((1H-imidazol-2-yl)methyl)-2-(1-((1r,4r)-4-(cyan...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493095![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387826![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493099![]() (N-(4-Cyanobenzyl)-2-(1-((1r,4r)-4-(cyanomethyl)cyc...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493100![]() (1-((1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihy...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493101![]() (2-((1r,4r)-4-(2-(Thiazol-4-ylmethyl)imidazo[4,5-d]...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | <0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493102![]() (2-((1S,4r)-4-(2-(2-((S)-3-Hydroxypyrrolidin-1-yl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493103![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493104![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM50527406![]() (CHEMBL4588333 | US10981911, Example 45) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493106![]() (Phenyl ((1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-1,6...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493107![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493108![]() (N-Benzyl-2-(1-((1r,4r)-4-(cyanomethyl)cyclohexyl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493109![]() (2-((1r,4r)-4-(2-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)im...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493110![]() (2-((1r,4r)-4-(2-(3-Hydroxy-3-phenylpyrrolidine-1-c...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493111![]() (2-((1r,4r)-4-(2-(2-Aminopyrimidin-5-yl)imidazo[4,5...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493112![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493113![]() (2-((1r,4r)-4-(2-(2-Aminopyrimidin-4-yl)imidazo[4,5...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493114![]() (4-(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-di...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387827![]() (N-(4-(Cyanomethyl)bicyclo[2.2.1]heptan-1-yl)-2-(1-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493116![]() (2-((1r,4r)-4-(2-(1H-Imidazol-2-yl)imidazo[4,5-d]py...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM50527410![]() (CHEMBL4439418 | US10981911, Example 57) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493131![]() (2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM493263![]() (N-(2-(2-(2-Aminoethoxy)ethoxy)ethyl)-2-(1-((1r,4r)...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Tyrosine-protein kinase JAK1 [574-1154] (Homo sapiens (Human)) | BDBM387819![]() (2-((1r,4r)-4-(2-(1H-Imidazol-4-yl)imidazo[4,5-d]py...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | 0.200 | n/a | n/a | n/a | n/a | n/a | n/a |
Janssen Pharmaceutica NV US Patent | Assay Description 11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut... | US Patent US10981911 (2021) BindingDB Entry DOI: 10.7270/Q27P92G6 | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 840 total ) | Next | Last >> |